Insuline dégludec : mode d'action et profil pharmacocinétique

Basal insulin analogues aim at mimicking basal physiologic insulin needs. Consistently, a new-generation of basal insulin has been developed: insulin degludec. This molecule has the ability to self-assemble into multihexamers following subcutaneous administration, which results in a very protracted absorption rate. Pharmacokinetics studies in patients with type 1 and type 2 diabetes receiving insulin degludec once daily have shown that insulin degludec has flat and stable pharmacokinetics profile with an ultra-long duration of action (>42 h).